EUVIMEDEUVIMED entdecken
Übersichtsarbeit

The roles of ROCK1 and ROCK2 in cardiopulmonary and fibrotic disease: considerations for pan-ROCK inhibition as a therapeutic approach

Marcia Kathryn Steiner, Emma Vontz, Serra Elliott, Scott Turner, Mardi Gomberg-Maitland, Jeremy Feldman, Madelyn Segna, William Marshall

Expert Review of Clinical Pharmacology · 10.11.2026

DOI: 10.1080/17512433.2026.2763167 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Expert Review of Clinical Pharmacology, online erschienen am 10.11.2026. Verfasst von Marcia Kathryn Steiner und 7 weiteren Autor:innen. Beteiligte Einrichtung: AllRock Bio Inc., Natick, MA, USA. Die Arbeit nennt 155 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: The Rho-associated protein kinase (ROCK) isoforms, ROCK1 and ROCK2, are central regulators of cellular functions fundamental to the pathogenesis of cardiopulmonary and fibrotic diseases. Evidence from animal and cellular models demonstrates ROCK signaling attenuation exerts potent effects on the dysregulated hyperproliferative, fibrotic, and contractile cellular components of the vascular wall and lung parenchyma. These aberrant cellular processes are central to the pathobiology of diverse cardiopulmonary diseases, including pulmonary hypertension and interstitial lung disease, where effective treatment options remain limited. Both pan-ROCK and ROCK2-selective inhibitors are approved for various diseases. The ongoing development of more potent or isoform-selective ROCK inhibitors across emerging indications highlights an unrealized potential. AREAS COVERED: The roles of ROCK1 and ROCK2 in tissue remodeling, inflammatory recruitment, and dysfunction in multiple cell types. Searches utilized keywords: 'pulmonary hypertension' or 'cardiopulmonary fibrosis' AND variations on 'ROCK inhibitor' and hand searching of key publications. EXPERT OPINION: Evidence suggests that pan-ROCK inhibitors may have certain advantages over ROCK2-selective agents for complex cardiopulmonary and fibrotic diseases, as each isoform plays distinct, non-redundant roles in fibrosis and inflammation. Concerns about hypotension as a dose-limiting side effect unique to pan-ROCK inhibition versus ROCK2 inhibition are increasingly unsupported by clinical data.

Schlagwörter

Stichwörter der Autor:innen

FibrosisROCK1ROCK2Rho-associated protein kinase (ROCK)interstitial lung disease (ILD)pan-ROCK inhibitionpulmonary arterial hypertension (PAH)vascular remodeling

Autor:innen und Institutionen

  • AllRock Bio Inc., Natick, MA, USA.
  • The George Washington University School of Medicine and Health Sciences, Washington, DC, USA.
  • Summit Medical Group, Bend, OR, USA.

Zitieren

APA

Steiner, M. K., Vontz, E., Elliott, S., Turner, S., Gomberg-Maitland, M., Feldman, J., Segna, M., & Marshall, W. (2026). The roles of ROCK1 and ROCK2 in cardiopulmonary and fibrotic disease: considerations for pan-ROCK inhibition as a therapeutic approach. Expert Review of Clinical Pharmacology. https://doi.org/10.1080/17512433.2026.2763167

Vancouver

Steiner MK, Vontz E, Elliott S, Turner S, Gomberg-Maitland M, Feldman J, et al. The roles of ROCK1 and ROCK2 in cardiopulmonary and fibrotic disease: considerations for pan-ROCK inhibition as a therapeutic approach. Expert Review of Clinical Pharmacology. 2026. doi:10.1080/17512433.2026.2763167

BibTeX
@article{Steiner2026,
  author = {Steiner, Marcia Kathryn and Vontz, Emma and Elliott, Serra and Turner, Scott and Gomberg-Maitland, Mardi and Feldman, Jeremy and Segna, Madelyn and Marshall, William},
  title = {The roles of ROCK1 and ROCK2 in cardiopulmonary and fibrotic disease: considerations for pan-ROCK inhibition as a therapeutic approach},
  journal = {Expert Review of Clinical Pharmacology},
  year = {2026},
  doi = {10.1080/17512433.2026.2763167}
}
Kostenlos starten →